ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. for treating unresectable or metastatic HER2 low or HER2 ultralow breast cancer in patients who have undergone specific prior treatments

The designation is based on positive results from the DESTINY-Breast06 phase 3 trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting

ENHERTU, a HER2-directed antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca, has now received eight Breakthrough Therapy Designations, including four for metastatic breast cancer

The Breakthrough Therapy Designation aims to expedite the development and review of medicines for serious conditions that show significant improvement over existing treatments

This new designation for ENHERTU marks the eleventh Breakthrough Therapy Designation in Daiichi Sankyo’s oncology pipeline